A health economic analysis of the use of rhBMP-2 in Gustilo-Anderson grade III open tibial fractures for the UK, Germany, and France

The purpose of this study was to determine the cost savings from a societal perspective for recombinant human Bone Morphogenetic Protein-2 (rhBMP-2) in grade III A and B open tibial fractures treated with a locked intramedullary nail and soft-tissue management in the UK, Germany, and France. Health care system costs (direct health care costs) and costs for productivity losses (indirect health care costs) were Calculated using the raw data from the Bone Morphogenetic Protein Evaluation Group in Surgery for Tibial Trauma "BESTT study". Return-to-work time for estimation of productivity losses was assumed to correspond with the time of fracture healing. For calculation of secondary interventions costs and productivity losses the respective 2007/2008 national tariffs for Surgical procedures and average national wages for the UK, Germany, and France were used. For a 1 year perspective, overall treatment costs per patient after the initial surgery of the control vs. the rhBMP-2 group were (Sic)44,757 vs. (sic)36,847 for the UK, (sic)50,197 vs. (sic)40,927 for Germany and (sic)48,766 vs. (sic)39,474 for France in favour of rhBMP-2 with overall savings overall savings per case of rhBMP-2 treatment of (sic)7911 for the UK, (sic)9270 for Germany, and (sic)9291 for France which was mainly due to reduced productivity losses by significant faster fracture healing in the rhBMP-2 group (p = 0.01). These savings largely offset the upfront price of rhBMP-2 of (sic)2266 (1790) pound in the UK, (sic)2970 in Germany, and (sic)2950 in France. Total net savings can be estimated to be (sic)9.6 million for the UK, (sic)14.5 million for Germany, and (sic)11.4 million for France. The results depend on the methodology used particularly for calculation of productivity losses and return-to-work time which was assumed to correspond with fracture healing time. In summary, despite the apparent high direct cost of rhBMP-2 in grade III A and B open tibial fractures, at a national level there are net cost savings from a societal perspective for all three countries. (C) 2009 Elsevier Ltd. All rights reserved.